JPMorgan Chase & Co. Trims Sarepta Therapeutics (NASDAQ:SRPT) Target Price to $175.00

Sarepta Therapeutics (NASDAQ:SRPT) had its target price lowered by JPMorgan Chase & Co. from $177.00 to $175.00 in a report released on Friday, Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock.

Other equities analysts have also issued research reports about the company. Cantor Fitzgerald reissued a neutral rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, May 2nd. Wedbush reissued an outperform rating and set a $224.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Needham & Company LLC restated a buy rating and set a $166.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, May 2nd. UBS Group boosted their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a buy rating in a report on Friday, March 1st. Finally, Royal Bank of Canada increased their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the company an outperform rating in a research note on Thursday, February 29th. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of Moderate Buy and a consensus target price of $160.60.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $135.04 on Friday. The firm has a 50-day simple moving average of $125.58 and a 200-day simple moving average of $110.89. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $12.76 billion, a price-to-earnings ratio of 1,227.64 and a beta of 0.95. Sarepta Therapeutics has a 52 week low of $55.25 and a 52 week high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. The company had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. Sarepta Therapeutics’s quarterly revenue was up 63.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.44) EPS. On average, equities analysts predict that Sarepta Therapeutics will post 2.23 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Bilal Arif sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the sale, the insider now directly owns 26,836 shares of the company’s stock, valued at approximately $3,457,550.24. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the transaction, the insider now directly owns 26,836 shares of the company’s stock, valued at approximately $3,457,550.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Ian Michael Estepan sold 1,200 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.30, for a total value of $153,960.00. Following the completion of the sale, the chief financial officer now directly owns 39,114 shares in the company, valued at approximately $5,018,326.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 25,731 shares of company stock valued at $3,248,319. 7.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 87 shares during the last quarter. Vanguard Capital Wealth Advisors lifted its holdings in Sarepta Therapeutics by 3.8% during the 4th quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock worth $236,000 after buying an additional 90 shares during the last quarter. DMC Group LLC boosted its position in shares of Sarepta Therapeutics by 2.9% during the 3rd quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock worth $400,000 after acquiring an additional 93 shares in the last quarter. Riggs Asset Managment Co. Inc. increased its holdings in shares of Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 125 shares during the last quarter. Finally, WCM Investment Management LLC raised its position in shares of Sarepta Therapeutics by 2.3% during the 1st quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock worth $813,000 after acquiring an additional 142 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.